TME Pharma Resumes Studies on NOX-E36 Following Termination of Collaboration with SERI
TME Pharma announces the launch of additional studies on its drug candidate NOX-E36 for filtering surgery of glaucoma in January 2026, after ending its collaboration with the Singapore Eye Research Institute. The company reports having approximately 2.0 million euros in cash reserves at the end of 2025.
End of Partnership with SERI and Future Plans for NOX-E36
TME Pharma has terminated its partnership with the Singapore Eye Research Institute for the development of NOX-E36 in filtering surgery for glaucoma, a decision announced on June 18, 2025, and described by the company as unrelated to the product's quality. According to the press release, the company will launch studies in January 2026 to validate the detection of NOX-E36 in a toxicologically relevant animal, a necessary first step before local administration to patients. The costs of this initial study are described as limited by the company. TME Pharma indicates that this new program should facilitate the search for a new partner to continue the development of NOX-E36, whether through collaboration, spin-off, sale, or joint venture. The company emphasizes that fibrosis, the target of NOX-E36, is a major factor in the failure of filtering surgery for glaucoma and affects several ocular diseases impacting approximately 30 million people in the United States.
Ongoing Discussions for NOX-A12 and Financial Strategy
Regarding NOX-A12, TME Pharma continues discussions with potential partners and has kept the clinical trial for glioblastoma open to resume as soon as an appropriate partner is found. The company plans to present a clear update and strategy to the market in the coming weeks. Financially, the group closed the year 2025 with approximately 2.0 million euros in available cash, compared to 2.06 million euros on June 30, 2025, which the company describes as reflecting a responsible cash management policy and strict cost control. TME Pharma announced on June 30, 2025, a new cash policy allowing investment in high-risk assets such as cryptocurrencies, but specifies that no interesting opportunities have arisen to date and no investments have been made in the cryptocurrency markets.
Non-Binding Letter of Intent with German Resource Development Company
On November 5, 2025, TME Pharma announced the signing of a non-binding letter of intent with a German resource development company, referred to by the acronym GRDC. According to the press release, discussions with this partner are ongoing and due diligence is underway. The company indicates that only positive results and the belief that the transaction will create significant value will lead to submitting the operation for shareholder approval. CEO Diede van den Ouden states that all options for the NOX-E36 and NOX-A12 programs are being considered, emphasizing that only partnerships likely to create significant value for shareholders will be presented. TME Pharma describes itself as a clinical-stage biotechnology company specializing in the development of innovative therapies for cancer and eye diseases.
